Brickell Total Debt Trend from 2010 to 2022
BBI  Stock  USD 3.50 0.14 4.17% 
Brickell  Total Debt 
Check Brickell Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brickell main balance sheet or income statement drivers, such as Direct Expenses of 1.7 M, Cost of Revenue of 7.3 M or Gross Profit of 414.6 K, as well as many exotic indicators such as PPandE Turnover of 4.69, Accounts Payable Turnover of 2.36 or Accrued Expenses Turnover of 0.54. Brickell financial statements analysis is a perfect complement when working with Brickell Biotech Valuation or Volatility modules. It can also supplement various Brickell Biotech Technical models . Continue to the analysis of Brickell Biotech Correlation against competitors.
Brickell Biotech Quarterly Total Debt  0.0 
Brickell Total Debt Breakdown
Showing smoothed Total Debt of Brickell Biotech with missing and latest data points interpolated. Total Debt of Brickell Biotech is a combination of both Brickell Biotech shortterm and longterm liabilities. Shortterm debts are those that must be paid back within a year. This type of debt applies to things like lines of credit or shortterm term bonds. Longterm debt of Brickell Biotech includes liability that must be paid off in more than a year. This typically includes large senior debts like mortgages, bonds, as well as business loans or leases. A component of Total Liabilities representing the total amount of current and noncurrent debt owed. Includes secured and unsecured bonds issued; commercial paper; notes payable; credit facilities; lines of credit; capital lease obligations; operating lease obligations; and convertible notes.Brickell Biotech's Total Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Brickell Biotech's overall financial position and show how it may be relating to other accounts over time.
View  Last Reported 53 K  10 Years Trend 

Total Debt 
Share
Timeline 
Brickell Total Debt Regression Statistics
Arithmetic Mean  3,312,150  
Geometric Mean  1,926,621  
Coefficient Of Variation  62.60  
Mean Deviation  1,837,177  
Median  4,639,000  
Standard Deviation  2,073,291  
Range  4,566,000  
RValue  (0.80)  
RSquared  0.63  
Significance  0.001127  
Slope  (423,882) 
Brickell Total Debt History
Other Fundumenentals of Brickell Biotech
Brickell Biotech Total Debt component correlations
Click cells to compare fundamentals
About Brickell Biotech Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Brickell Biotech income statement, its balance sheet, and the statement of cash flows. Brickell Biotech investors use historical funamental indicators, such as Brickell Biotech's Total Debt, to determine how well the company is positioned to perform in the future. Although Brickell Biotech investors may use each financial statement separately, they are all related. The changes in Brickell Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brickell Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Brickell Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Brickell Biotech. Please read more on our technical analysis and fundamental analysis pages.
Brickell Biotech, Inc., a clinicalstage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis BBI02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases and BBI10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as nextgeneration kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Last Reported  Projected for 2022  
Total Debt  393.3 K  403.6 K 
Be your own money manager
Our tools can tell you how much better you can do entering a position in Brickell Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.riskadjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated 
All Next  Launch Module 
Pair Trading with Brickell Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Brickell Biotech
0.87  ABVC  Abvc Biopharma  Earnings Call This Week  PairCorr  
0.67  ACER  Acer Therapeutics  Earnings Call This Week  PairCorr 
Moving against Brickell Biotech
0.81  AVXL  Anavex Lf SC  Fiscal Year End 23rd of November 2022  PairCorr  
0.79  ARWR  Arrowhead Pharma  Fiscal Year End 28th of November 2022  PairCorr  
0.74  ACLX  Arcellx  Earnings Call This Week  PairCorr  
0.71  RIVN  Rivian Automotive  Downward Rally  PairCorr 
The ability to find closely correlated positions to Brickell Biotech could be a great tool in your taxloss harvesting strategies, allowing investors a quick way to find a similarenough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech  that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between 1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better riskadjusted return on your portfolios.Continue to the analysis of Brickell Biotech Correlation against competitors. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Brickell Stock analysis
When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios  Go  
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities  Go  
Watchlist OptimizationOptimize watchlists to build efficient portfolio or rebalance existing positions based on meanvariance optimization algorithm  Go  
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk  Go  
Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon  Go  
Piotroski F ScoreGet Piotroski F Score based on binary analysis strategy of nine different fundamentals  Go  
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges  Go 
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization 8.9 M  Quarterly Revenue Growth YOY 27.58  Return On Assets 0.85  Return On Equity 1.76 
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.